The QualityStocks Daily Tuesday, August 13th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (BDWYF) +400.00%

Schaeffer's (DCPH) +79.95%

Marketbeat.com (LKSD) +23.76%

The QualityStocks Daily Stock List

Windtree Therapeutics, Inc. (WINT)

Zacks, Barchart, Super Stock Screener, Investing Note, Modest Money, Investors Village, Simply Wall St, MacroTrends, Infront Analytics, Clay Trader, AI StockFinder, Wallet Investor, OTC Markets, Insider Financial, Marketbeat, Investors Hangout, InvestorsHub, Insider Tracking, PR Newswire, Market Screener, Biz Journals, Annual Reports, and Stockhouse reported previously on Windtree Therapeutics, Inc. (WINT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Windtree Therapeutics, Inc. is a clinical-stage, biopharmaceutical and medical device company based in Warrington, Pennsylvania. It concentrates on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four programs in clinical development and manifold pre-clinical programs that span respiratory and cardiovascular disease states. Windtree Therapeutics lists on the OTCQB.

Three of Windtree’s clinical programs are in late-stage development. They include AEROSURF®, an innovative combination drug/device product candidate designed to deliver the Company's proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS).

In addition, Windtree Therapeutics has its istaroxime. This is a novel, dual-acting agent undergoing development to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments. Windtree also has its rostafuroxin. This is a novel precision drug product undergoing development to target hypertensive patients with certain genetic profiles in the important group of patients with resistant hypertension. Moreover, the Company has numerous pre-clinical products. This includes potential heart failure therapies delivered orally that are based on SERCA2a mechanism of action.

Recently, Windtree Therapeutics and Eleison Pharmaceuticals LLC jointly announced positive results of the feasibility study using Windtree's proprietary Aerosol Delivery System (ADS) aerosolization technology to deliver Eleison's inhaled lipid cisplatin (ILC). Eleison Pharmaceuticals is a specialty pharmaceutical company developing life-saving therapeutics for rare cancers.

Eleison has an exclusive global license to ILC. This is a novel, sustained-release formulation of cisplatin in a nanoscale lipid-based complex administered through inhalation or intraperitoneally. ILC, when administered by inhalation, can deliver high levels of sustained release cisplatin targeted to the lung, with minimal systemic-related toxicities. Eleison Pharmaceuticals is developing ILC for lung cancer. It completed a phase 2 study of ILC in patients with bone cancer (osteosarcoma) metastatic to the lung. The feasibility assessment demonstrated that Windtree's ADS technology can effectively aerosolize ILC and at a higher volume versus conventional nebulizer technology.

Windtree Therapeutics, Inc. (WINT), closed Tuesday's trading session at $3.90, even for the day, on 13 volume with 1 trade. The average volume for the last 3 months is 818 and the stock's 52-week low/high is $2.04999995/$5.3499999.

chart

NervGen Pharma Corp. (NGENF)

InvestorX, Market Screener, Stock Target Advisor, Investor Ideas, Investors Hangout, Stockhouse, MarketWatch, and Trading View reported earlier on NervGen Pharma Corp. (NGENF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company based in Vancouver, British Columbia. Its dedication is to creating pioneering solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. The Company’s lead compound is NVG-291. NervGen Pharma lists on the OTC Markets’ OTCQX.

The Company’s core technology targets protein tyrosine phosphatase sigma (PTPσ). This is a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions. Research has been conducted on other applications of PTPs including MS, stroke, cardiac arrhythmia, and Alzheimer’s Disease.

NervGen Pharma also continues to research secondary applications such as multiple sclerosis, acute myocardial infarction induced arrhythmia (AMI, commonly known as a heart attack), stroke and other neurodegenerative diseases.

The Company’s plan is to start a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA). NervGen is advancing NVG-291 for the treatment of spinal cord injury as it believes this indication is a major opportunity because of the current lack of non-surgical solutions in the market, the considerable impact on quality of life, and the high cost burden to the healthcare system.

NervGen Pharma’s belief is that NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury. In addition, the Company believes that NVG-291 as a therapy could empower these patients to live more active and productive lives.

Last month, NervGen Pharma reported the publication of a new, independent study using the Company's core Intracellular Sigma Peptide (ISP) technology in a mouse model representative of demyelination in multiple sclerosis. The peer reviewed paper is titled "Modulating Proteoglycan Receptor PTPσ Using Intracellular Sigma Peptide Improves Remyelination and Functional Recovery in Mice with Demyelinated Optic Chiasm".

Mr. Ernest Wong, President & Chief Executive Officer of NervGen Pharma, said, "A cornerstone of our technology is the validation of our science in different preclinical models by independent research groups around the world."

NervGen Pharma Corp. (NGENF), closed Tuesday's trading session at $1.0635, even for the day, on 20,000 volume. The average volume for the last 3 months is 5,718 and the stock's 52-week low/high is $0.949999988/$1.52499997.

chart

AMMO, Inc. (POWW)

Wallet Investor, YCharts, Barchart, The Street, Stockopedia, Seeking Alpha, Stockwatch, Dividend Investor, Stockhouse, Infront Analytics, Simply Wall St, GlobeNewswire, GuruFocus, Morningstar, 4-Traders, InvestorsHub, Stockawiki, Investors Hangout, Business Insider, Market Screener, Trading View, and MarketWatch reported earlier on AMMO, Inc. (POWW), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and premier American ammunitions manufacturer that designs and manufactures products for a variety of aptitudes. This includes law enforcement, military, hunting, sport shooting and self-defence. Established in 2016, AMMO is headquartered in Scottsdale, Arizona. The Company operates a munitions manufacturing facility in Payson, Arizona, and a brass casings manufacturing facility in Manitowoc, Wisconsin.

The ammunition AMMO builds performs like high end custom hand loaded ammunition. The Company works to be the leading innovator of center-fire ammunition for military, law enforcement, and civilians. Every load is developed for a specific purpose.

The focus is on consistency, accuracy, and, in some cases, felt recoil. Each round is designed, manufactured, inspected and packaged to bring a first-rate shooting experience to AMMO’s end consumer. In addition, AMMO’s HyperClean technology enables its customers to shoot more and clean less.

AMMO promotes branded munitions. These include its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, O.W.L. Technologies®, TAC-PTM Tactical Precision Defense munitions, and OPS (One Precise Shot). OPS is a lead-free frangible tactical line of munitions for self-defence.

AMMO closed this year the strategic acquisition of Jagemann Sporting Group’s Wisconsin Casings division (Jagemann Casings). Jagemann’s Casing Division is located in Manitowoc Wisconsin, the headquarters for Jagemann Stamping, the 73-year-old parent company established to serve the automotive industry with specialty precision metal stamped parts. The manufacturing operations will remain in Manitowoc, Wisconsin.

Last month, AMMO provided a business update in conjunction with the preannouncement of its fiscal first quarter sales, ended June 30, 2019. For Fiscal Q1 2020, ended June 30, 2019, preliminary Revenues are $4.3 Million. The Company expects Revenue of at least $6.5 Million for the Fiscal Second Quarter. This represents sequential growth of greater than 50 percent. AMMO anticipates achieving positive Cash Flow in the second half of Calendar 2019.

Mr. Fred Wagenhals, AMMO Chief Executive Officer, said, “Fiscal first quarter was pivotal for AMMO on a variety of fronts, but most notably was the integration of our recent acquisition, JMC, into our business. Our manufacturing footprint is now aligned and optimized to meet the growing needs of customers demanding difficult to source brass components, as well as our innovative line of projectiles that address a variety of unmet needs in the marketplace.”

AMMO, Inc. (POWW), closed Tuesday's trading session at $2.00, off by 1.9608%, on 10,435 volume with 8 trades. The average volume for the last 3 months is 15,059 and the stock's 52-week low/high is $1.02999997/$4.67999982.

chart

Flower One Holdings, Inc. (FLOOF)

Pot Stock News, Cash Crop Today, Street Insider, Investor Ideas, Trading View, Dividend Investor, Stockwatch, Investors Hangout, Invest Tribune, Investing News, Stockhouse, New Cannabis Ventures, and InvestorsHub reported earlier on Flower One Holdings, Inc. (FLOOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is on the fast track to becoming the leading cannabis cultivator, producer and innovator in the State of Nevada. It owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms. Additionally, the Company owns the established NLV Organics consumer brand of cannabis products. Flower One Holdings is based in Toronto, Ontario.

The Company is completely licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in Nevada. Currently, Flower One holds licensing agreements with its Brand Partners - Flyte Concentrates, Rapid-Dose Therapeutics' Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, Grenco Science (G Pen), and The Medicine Cabinet.

Flower One is converting its 455,000 square-foot greenhouse and production facility for cultivating and processing high-quality cannabis at scale. This facility is the largest in the State of Nevada. Combined, the flagship greenhouse facility and production facility (once completely operational) and the North Las Vegas facility provide the Company with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products.

In July, Flower One Holdings announced a licensing agreement with Los Angeles, California-based Deuces 22. This the new premium-quality, lifestyle cannabis brand founded by four-time NBA champion John Salley, and daughter Tyla Salley.

Deuces 22 centers on providing cannabis consumers with access to locally-produced, high-quality flower. Moreover, the cannabis brand has established an inclusive and informative educational platform, Deuces Academy, aimed at lessening the complexity of cannabis for consumers of all experiences and levels of sophistication.

Flower One is now licensed to manufacture, distribute, and sell Deuces 22's selection of high-quality dry flower and pre-rolls in Nevada. This is the U.S.-market debut of Deuces 22. The Deuces 22 merchandise line – including t-shirts with graphic designs reading "#VeganAF" or "SATIVA" – will also be available in Nevada. Vape pens, edibles, CBD topicals, among other products, will follow in the near future.

Flower One Holdings will release its 2019 Q2 financial results today after market close. The Company will host a conference call on Wednesday, August 14, 2019 at 8:30 a.m. ET to discuss its financial results and review recent and upcoming milestones.

Flower One Holdings, Inc. (FLOOF), closed Tuesday's trading session at $1.9382, up 1.4764%, on 86,918 volume with 109 trades. The average volume for the last 3 months is 68,669 and the stock's 52-week low/high is $0.879999995/$2.80999994.

chart

Nephros, Inc. (NEPH)

Zacks, StreetWise Reports, GlobeNewswire, Stockwatch, Simply Wall St, Proactive Investors, Market Screener, Wallet Investor, Last10k, OTC Markets, and Stockhouse reported previously on Nephros, Inc. (NEPH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nephros, Inc. is a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets. Nephros filters, including AETHER™ brand filters, improve the taste and odor of water and lessen biofilm, bacteria, and scale build-up in downstream equipment. Nephros and AETHER™ products are used in the health care, food service, hospitality, as well as convenience store markets. OTCQB-listed, Nephros is headquartered in South Orange, New Jersey.

The Company’s ultrafilters are used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas) and viruses from water. These ultrafilters provide barriers that assist in improving infection control in showers, sinks, and ice machines.

Furthermore, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of endotoxins and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients. Nephros offers Infection Control Ultrafilters, Dialysis Ultrafilters, and Commercial Ultrafilters.

Last week, Nephros announced financial results for the three months ended June 30, 2019. Product Revenue was $2.3 million, up 88 percent versus $1.2 million in 2018. Net Revenue was also $2.3 million, up 69 percent versus $1.4 million in 2018.

Net Loss in the Water Filtration business segment was $0.5 million. This represents an improvement of 8 percent versus a Net Loss of $0.6 million in Q2 2018. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) in the Water Filtration business segment was ($0.1) million. This represents an improvement of 62 percent versus ($0.3) million in Q2 2018.

Today, Nephros announced that its common shares have been approved to list on the Nasdaq Capital Market. The Company expects its common stock to commence trading on the Nasdaq Capital Market at the opening of trading on August 14, 2019. The stock will trade under its existing CUSIP number 640671400, and its existing ticker symbol “NEPH.”

Nephros, Inc. (NEPH), closed Tuesday's trading session at $6.65, up 5.5556%, on 25,583 volume with 49 trades. The average volume for the last 3 months is 27,524 and the stock's 52-week low/high is $3.69000005/$6.75.

chart

Teranga Gold Corporation (TGCDF)

Invest Tribune, Mining Stock Valuator, TipRanks, 24hourgold, InvestorsHub, Short Squeeze, Wallet Investor, Market Screener, Dividend Investor, Street Insider, Equity Clock, and Stockhouse reported beforehand on Teranga Gold Corporation (TGCDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Teranga Gold Corporation engages in the exploration, development, production, and sale of gold in West Africa. It is a multi-jurisdictional West African gold company also focused on the exploration of approximately 6,400 km2 of land located on prospective gold belts. The Company’s projects include Sabodala, Wahgnion, and Golden Hill. Teranga Gold is in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQX.

The Sabodala gold mine is located in the Republic of Senegal. The Wahgnion gold project is located in Burkina Faso. The 100 percent owned Golden Hill project is located in southwestern Burkina Faso on the Houndé belt. Golden Hill includes three exploration permits covering an area of about 468 square kilometers.

Teranga Gold also develops and explores different projects in Burkina Faso, Côte d'Ivoire, and Senegal. Since its initial public offering in 2010, Teranga Gold has produced more than 1.7 million ounces of gold at its Sabodala operation in Senegal. The Company had greater than 4.0 million ounces of gold reserves as of June 30, 2018.

In July, Teranga Gold announced an extensive drilling and exploration program during the second half of 2019 at Golden Hill. This is an advanced-stage exploration project that has delivered multiple near-surface and high-grade gold discoveries over the last two years. The Company owns 100 percent of Golden Hill, located within the central part of the Houndé Greenstone Belt, a highly mineralized gold zone in southwest Burkina Faso, West Africa that is presently home to three operating gold mines.

The estimation is that Golden Hill’s budget for drilling and exploration in the second half of 2019 will be at least $5 million. It will be financed by the Golden Hill tranche of the Taurus debt facility. This $25-million tranche is intended to advance the project through the feasibility stage of development.

For the three months ended June 30, 2019 versus the three months ended June 30, 2018, Teranga Gold had second quarter gold production of 63,436 ounces. This is 3 percent lower than last year’s record Q2.

At Wahgnion, construction has continued to progress well during the quarter. First gold pour remains on schedule and ahead of the National Instrument 43-101 Standards of Disclosure for Mineral Projects (NI 43-101) technical report initially released on October 31, 2018. Most of the project is constructed and the initial stages of commissioning and operating handover processes have started.

Teranga Gold Corporation (TGCDF), closed Tuesday's trading session at $4.1216, off by 1.8667%, on 82,299 volume with 68 trades. The average volume for the last 3 months is 23,779 and the stock's 52-week low/high is $2.2262001/$4.26000022.

chart

Wealth Minerals Ltd. (WMLLF)

NetworkNewsWire, Zacks, StreetWise Reports, Stocks.TradingCharts, Proactive Investors, Investing News, GlobeNewswire, Stockhouse, and Junior Mining Network reported previously on Wealth Minerals Ltd. (WMLLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wealth Minerals Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada, Mexico, Peru, and Chile. The Company’s principal focus is the acquisition and development of lithium projects in South America. To date, Wealth Minerals has positioned itself to develop the Atacama Project alongside existing producers in the prolific Atacama region, where the Company has a substantial licenses package. A junior mineral resource exploration company and listed on the OTCQX, Wealth Minerals is based in Vancouver, British Columbia.

Concerning the Atacama Salar in Chile, Wealth Minerals has a large land position in the lithium industry’s leading salar. Its development plans are to follow upon the success of third party production facilities south of its land position in the Atacama Salar. The concessions cover an area of about 46,200 hectares in the northern part of the Atacama Salar, in Region II of Chile. The Salar de Atacama is host to more than 15 percent of the world’s known lithium reserves.

In addition, Wealth Minerals has its Laguna Verde Project in Chile. The Company has an aggregate total concession size of roughly 6,300 hectares in Region III, northern Chile. Currently, Wealth Minerals is analyzing data collected from field work studies. This includes resistivity tests that are very accurate for locating subsurface brines. The result of the analysis will give the Company drill targets that will be drilled once the seasonal factors permit so.

Wealth Minerals also has its Trinity Project. Trinity comprises several land positions located in close proximity to each other. Quisquiro North And South are the Trinity Project. This is where anticipated future infrastructure and management synergies can help exploit the assets’ lithium potential. Also, Wealth Minerals maintains and continues to evaluate a portfolio of precious and base metal exploration-stage projects.

Recently, Wealth Minerals announced that it strengthened its Board of Directors with the appointment of Mr. David Lies as a Director. Additionally, the Company announced the appointment of Mr. Kenneth Strong as its Senior Advisor of Sustainability. Mr. Lies is an entrepreneur and private equity investor with a focus on the real estate and manufacturing sectors. Mr. Strong has a multi-decade career centered on connecting capital markets with global resource sustainability.

Last week, Wealth Minerals announced that it arranged a non-brokered private placement of up to 3,500,000 units at a price of $0.35 per Unit for gross proceeds of up to $1,225,000. The net proceeds from the Offering are intended to be used to fund exploration and development of the Company’s Atacama Project and also general corporate purposes.

Wealth Minerals Ltd. (WMLLF), closed Tuesday's trading session at $0.3149, up 1.7447%, on 81,900 volume with 20 trades. The average volume for the last 3 months is 134,304 and the stock's 52-week low/high is $0.223399996/$0.638599991.

chart

A.M. Castle & Co. (CTAM)

Tip Ranks, Stockhouse, GuruFocus, Simply Wall St, Barchart, YCharts, Wallet Investor, StockTwits, Jet Life Penny Stocks, Stockwolf, Penny Stock Hub, MarketWatch, The Street, Morningstar, InvestorsHub, TradingView, Stockwatch, and Whale Wisdom reported earlier on A.M. Castle & Co. (CTAM), and we also report on the Company, here at the QualityStocks Daily Newsletter.

A.M. Castle & Co., together with its subsidiaries, operates as a specialty metals distribution company in the United States, Canada, Mexico, and internationally. As of March 13, 2018, it operated 22 metals service centers. A.M. Castle distributes engineered specialty grades and alloys of metals. Additionally, the Company offers specialized processing services. OTCQX-listed, A.M. Castle has its head office in Oak Brook, Illinois.

The Company also performs varied specialized fabrications for its customers through subcontractors, which thermally process, turn, polish, and straighten alloy and carbon bars. A. M. Castle primarily serves Fortune 500 companies, and medium and smaller sized firms operating in the producer durable equipment, aerospace, heavy industrial equipment, industrial goods, construction equipment, and retail sectors.

The Company works with worldwide original equipment manufacturers (OEMs) to better serve their multi-location production requirements and delivery needs. Also, A.M. Castle help the thousands of machine shops that service the OEMs or have their own niche end market.

A.M. Castle specializes in the distribution of alloy and stainless steels; nickel alloys; aluminum and carbon. The Company’s products include alloy, aluminum, nickel, stainless steel, carbon, and titanium in plate, sheet, extrusions, and round bar. Furthermore, its products include hexagon bar, square and flat bar, tubing, and coil forms.

A.M. Castle’s H-A Industries is a state-of-the art heat-treat and bar processing facility. H-A Industries provides a wide spectrum of thermal treating and finishing services. The Company also offers a complete range of value-added processing services for plate, sheet, tubing and bar products from locations throughout its network.

Concerning Oil & Gas, A.M. Castle’s metallurgical and supply chain expertise helps oil and gas customers meet unique specifications with stable supplies. Regarding Machine Shops, the Company can help a business operate efficiently and competitively. It accomplishes this through local facilities, first-rate inventory, as well as advanced processing.

Pertaining to Aerospace, A.M. Castle helps aerospace and defense companies navigate complex requirements, schedules, and subcontractor networks. Regarding Industrial, the Company customizes supply plans to customers across industrial sectors - from heavy equipment to semiconductors.

Recently, A. M. Castle & Co. announced that it qualified to trade on the OTCQX® Best Market after formerly trading on the OTCQB® Venture Market. The OTCQX® Best Market is reserved for companies meeting high financial standards, adhering to best corporate governance and compliance practices and requires a professional third-party sponsor introduction.

Chairman and Chief Executive Officer, Mr. Steve Scheinkman of A. M. Castle & Co. said, “Upgrading to OTCQX evidences A. M. Castle’s successful transformation since completing our financial restructuring in 2017. Moreover, we have now demonstrated an ability to generate positive EBITDA in excess of cash interest and are continuing to focus on improving the profitability of our core operations and executing strategic growth initiatives.”

A.M. Castle & Co. (CTAM), closed Tuesday's trading session at $1.83, up 1.6667%, on 3,994 volume with 21 trades. The average volume for the last 3 months is 1,031 and the stock's 52-week low/high is $1.58000004/$4.51000022.

chart

NewBridge Global Ventures, Inc. (NBGV)

Spotlight Growth, OTC Markets, Proactive Investors, GuruFocus, Stockhouse, Dividend Investor, Simply Wall St, 4-Traders, Morningstar, Infront Analytics, Stockflare, Penny Stock Hub, OTC Stock Picks, Central Charts, Wallet Investor, MarketWatch, InvestorsHub, and Investors Hangout reported earlier on NewBridge Global Ventures, Inc. (NBGV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NewBridge Global Ventures, Inc. concentrates on the developing legal and regulated cannabis industry. It provides business consulting services to companies operating within the legal medical cannabis and hemp related industries. The Company formerly went by the name NABUfit Global, Inc. It changed its corporate name to NewBridge Global Ventures, Inc. in December 2017. OTCQB-listed, NewBridge Global Ventures is based in Alameda, California.

The Company acquires and currently operates a vertically integrated portfolio of California cannabis and hemp companies. NewBridge’s vertical structure includes genetics, cloning, cultivation, manufacturing, distribution, and consulting services to industry entrepreneurs, and education for medical professionals. The Company focuses on compliance, industry best practices, standardization, as well as corporate governance.

NewBridge Global Ventures engages in management consulting and control and non-control acquisitions in the legal cannabis sector and its diverse verticals. The Company’s mission focuses on the global education of healthcare professionals and institutions, international producers, processors, and distributors, and ancillary/supporting technologies that can impact the globalal healthcare and wellness industries.

NewBridge Global Ventures’ portfolio "eco-system" consists of education, production and distribution companies. Its portfolio includes Elevated Education (EE); Roots of Cali; The Bay Clonery; 5Leaf; GENUS Consulting; Green Thumb Distributors; Mad Creek Farm; East 10th Street; East 11th Street; and Timothy.

Recently, NewBridge Global Ventures, announced that it expanded its corporate management team with the appointments of Dr. John MacKay as Chief Technology Officer (CTO), Mr. Patrick P. Tang as Chief Compliance Officer (CCO), and Ms. Sandra Ribble as Corporate Controller of NewBridge Global Ventures.

Mr. Bob Bench, NewBridge Global Ventures’ Interim President, said, “NewBridge Global Ventures is building a world class executive team to ensure that we continue to operate at the highest quality and compliance standards in the highly regulated cannabis industry. With ten operating subsidiaries in our vertically integrated corporate structure, it was important to add highly experienced professionals such as John, Pat, and Sandra to oversee technology, compliance and financial governance, key areas for excellence as we continue to scale our operations.”

NewBridge Global Ventures, Inc. (NBGV), closed Tuesday's trading session at $0.3401, up 21.4643%, on 50,104 volume with 27 trades. The average volume for the last 3 months is 1,031 and the stock's 52-week low/high is $0.208000004/$2.50.

chart

Sustainable Projects Group, Inc. (SPGX)

Infront Analytics, OTC Markets, Wallstreet Online, OTC Dynamics, Capital Cube, Market Exclusive, MarketWatch, Simply Wall Street, TradingView, OilandGas360, and 4-Traders reported on Sustainable Projects Group, Inc. (SPGX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Sustainable Projects Group, Inc. is a member of SP Group. Sustainable Projects is positioned to become a world leading natural resources holding and development company through value-based investments and collaborative partnerships with global leaders across the natural resources sector. SP Group has initiated its goals through pursuing investment and partnerships with some of the most diversified and integrated companies available on the market. OTCQB-listed, Sustainable Projects Group has its corporate office in Naples, Florida.

The Company is to invest into undervalued global companies via direct investment. Also, it is negotiating investment and collaboration agreements with different international leaders throughout the natural resource industry.

SP Group’s commitment is to negotiating working interests (WIs) in a broad array of natural resource projects worldwide. The Company uses the local knowledge and expertise of companies that operate its interests. Consequently, it benefits as non-operators from low-risk opportunities to provide a steady stream of resources to the global market.

SP Group chooses its investments and partnerships only from well established companies with a proven track record and that bring strong project experience to the Company. At present, SP Group is invested in a range of natural resources projects beyond its initial emphasis on oil and gas. Sustainable Projects Group announced in December 2017 the acquisition of myfactor.io AG. This is a business development company based in Liechtenstein.

Sustainable Projects Group is gaining direct access to a company with the experience and infrastructure to develop SME's and issue bonds. As part of its growth strategy for SME's, myfactor.io can place bonds in U.S. Dollars, Euros and Swiss Francs.

Sustainable Projects Group announced this past February the acquisition of a 10 percent stake in Falcon Projects AG. Falcon specializes in bridge financing and refinancing solutions in the construction and project development industry. With this acquisition, Sustainable Projects Group continues to broaden its network of investments and partners in varied industries. Headquartered in Zurich, Switzerland, Falcon Projects AG is presently providing financing solutions to a host of real estate development projects initiated by some of Europe's top project developers.

Sustainable Projects Group, Inc. (SPGX), closed Tuesday's trading session at $3.20, up 60.00%, on 200 volume with 2 trades. The average volume for the last 3 months is 265 and the stock's 52-week low/high is $1.00/$3.99.

chart

Natcore Technology, Inc. (NTCXF)

Stockhouse, InvestorsHub, MarketWatch, OTC Markets, Business Insider, and StreetInsider reported on Natcore Technology, Inc. (NTCXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Natcore Technology, Inc. concentrates on using its proprietary Foil Cell technology to considerably lower the costs and improve the power output of solar cells. The Company is creating the next generation of solar cells. Natcore is developing two main technologies. These are low-cost, all-back-contact solar cell structures, and Black Silicon cells.

A solar R&D company, Natcore Technology is headquartered in Rochester, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Foil Cell (All Back Contact Solar Cell) uses a high-speed, low temperature laser process. Natcore’s Black Silicon technology streamlines the path to low solar cell reflectance.

Natcore Technology has its Natcore Laboratory in Rochester. This is a 19,000 sq. ft. facility. It has 8,000 sq. ft. of ‘class 10,000’ clean room. The Company engages in the full solar cell process at this laboratory - from bare silicon wafer to working cells.

Regarding the Company’s Foil Cell Structure, the process involves multilayer foil metallization. Key features/properties include low cost contact metals and simplified manufacture. This includes low capital equipment cost, small factory footprint, and low temperature processing.

Natcore Technology has established exclusive licenses and/or joint research agreements with Rice University, the National Renewable Energy Laboratory (NREL), Fraunhofer ISE and the University of Virginia. The Company has received 33 patents; 32 patents are pending.

Recently, Natcore Technology announced it significantly streamlined the fabrication method for its pioneering Natcore Foil Cell™. This allows for even lower-cost production methods.

The Company is targeting greater than 25 percent real-world efficiency for its eventual production solar cells. This is approximately a 25 percent performance improvement over numerous high-end commercial cells being installed today.

The use of laser processing to create the Company’s unique, all-back-contact cell structure has been eliminated and replaced by a carrier selective contact process. This is combined with a foil metallization, which can be inexpensively made with high-speed roll-processing methods. Natcore has started an accelerated development program to produce a prototype with the new process, and also include production cost and efficiency modeling by independent authorities.

Natcore Technology, Inc. (NTCXF), closed Tuesday's trading session at $0.0249, up 77.8571%, on 20,010 volume with 1 trade. The average volume for the last 3 months is 25,531 and the stock's 52-week low/high is $0.001099999/$0.115000002.

chart

Broadway Gold Mining Ltd. (BDWYF)

Streetwise Reports, Stockhouse, Barchart, and InvestorsHub reported on Broadway Gold Mining Ltd. (BDWYF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A resource company, Broadway Gold Mining Ltd. centers on development-stage projects with advanced exploration potential. The Company owns a 100 percent interest in the Madison copper-gold project in the Butte-Anaconda mining region of Montana. Broadway Gold Mining’s shares trade on the OTC Markets Group’s OTCQB. The Company has its corporate office in Vancouver, British Columbia.

The Madison copper-gold project is permitted for exploration. It contains a past-producing underground mine that Broadway Gold Mining has refurbished. The Company is expanding known copper and gold zones, which remain open for development in the mine's perimeter.

Broadway’s exploration program has identified new anomalies across its wide-ranging land package. These provide drill targets believed to be associated with large-scale porphyry mineralization.

The Company identified copper-gold porphyry targets at Madison in 2017, supported by a newly assembled geological model. Phase I and II drilling this year returned high-grade gold and copper intersections from shallower skarn zones. Many high-priority targets, including porphyry, will be the emphasis of Phase III drilling.

Broadway Gold Mining recently announced the discovery of a new latite porphyry zone of mineralization at its Madison project in the legendary Butte-Anaconda mining region of Montana.

Mr. Duane Parnham, Broadway Gold Mining’s President and Chief Executive Officer, said, "Broadway's technical team has successfully delivered on a fourth major milestone worthy of additional testing by discovering a porphyry system underlying the shallower skarn zones, which were mined in the past and expanded in our recent drilling. Although indications suggest a typical copper porphyry alteration system is present, this new mineralization discovered at Madison exhibits similar characteristics to the latite porphyry hosted at Barrick's Golden Sunlight Mine (GSM) located 36 kilometers away in Whitehall, Montana."

Recently, Broadway Gold Mining announced that, as a result of its recent porphyry discovery, it has staked additional ground to cover favorable geological and geophysical targets in the area of its 100 percent-owned Madison copper-gold project.

The new claims are contiguous to the south of the Company’s active exploration area. The new claims extend the current Madison property footprint to 2,514 acres.

Broadway’s Phase III drilling program continues. The Company is fully funded for completion of the program. Deeper geophysical targets from the 2017 survey appear to trend through the original property boundary onto the newly acquired claims.

Broadway Gold Mining Ltd. (BDWYF), closed Tuesday's trading session at $0.05, up 400.00%, on 4,000 volume with 1 trade. The average volume for the last 3 months is 5,313 and the stock's 52-week low/high is $0.009999999/$0.129999995.

chart

Stealth Technologies, Inc. (STTH)

NetworkNewsWire and RedChip reported previously on Stealth Technologies, Inc. (STTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Stealth Technologies, Inc. is a technology business listed on the OTC Markets Group’s OTCQB. The Company previously went by the name Excelsis Investments, Inc. It changed its name to Stealth Technologies, Inc. in July 2016. Stealth Technologies engages in identifying and capitalizing on technology and associated markets. The Company produces products for personal and financial protection.

Incorporated in 2010, Stealth Technologies has its corporate office in Largo, Florida. It became public through a reverse merger in 2012.

Moreover, Stealth Technologies announced in March of this year the completion of five new products. Currently, these products are staged in a large direct response retailer's quality assurance and legal department. They are under final review to ensure that marketing claims associated with each product are accurate when measured against actual performance levels of each product, and that assurance and inventory is satisfactory and has met all quality control factors. Stealth Technologies’ strategic initiative is to expand its product footprint across varied industries and distributors.

The Company has developed a group of products to protect against "electronic pickpockets," emergency response latency, credit fraud protection, and cell phone data protection. Its initial product to market is the Stealth Card.

The design of the Stealth Card is to protect the Radio-Frequency Identification (RFID) chip in a consumer's credit card from electronic stealing or pickpocketing, which uses a smartphone, credit card reader, or RFID antenna to remotely access data stored on the consumer's Smartchip. Stealth Card renders the chipped information invisible to intrusion.

The Stealth Card is a 100 percent USA product. The Stealth Card is manufactured from Stealth Technologies’ laboratory and research/development facility in West Virginia to its manufacturing facility in Massachusetts.

Development for the Stealth Card started in 2012. This is when Company Founder and Chief Executive Officer (CEO), President, and Director, Mr. Brian McFadden, observed the worldwide shift towards smart chip card technology to transmit and process credit card/debit card transactions. With Europe and Asia already making the transition away from the magnetic strip to smart chip cards, Mr. McFadden believed the United States market would need to follow suit.

To use the Stealth Card, a person places a Stealth Card in their wallet, pocket, change purse or anywhere they carry their credit cards. One card can protect up to 12 cards in a wallet. The card can be physically placed anywhere in a wallet or pocket.

The card does not need to be in the front or back of one’s wallet. The Stealth Card provides effective protection irrespective of where it’s placed in relation to one’s credit cards.

Stealth Technologies previously announced the development of the 911 Help Now Generation II Product. The 911 Help Now product provides a direct two-way voice connection to emergency service providers. The 911 Help Now pendent works by pressing the Help Now button and then a person is connected.

Stealth Technologies has a number of other products under development. The Company is exploring potential military applications of its proprietary technologies.

Along with the Stealth Card and the 911 Help Now Generation II Product, Stealth Technologies’ portfolio includes Data Secure Plus, which is new to market. Its portfolio also includes Stealth Mobile.

Stealth Technologies, Inc. (STTH), closed Tuesday's trading session at $0.005, up 47.0588%, on 1,630,000 volume with 23 trades. The average volume for the last 3 months is 423,842 and the stock's 52-week low/high is $0.0026/$0.039999999.

chart

Ecosphere Technologies, Inc. (ESPH)

TheMicrocapNews, PennyStocks24, Buzz Stocks, Penny Pick Finders, PennyStockProphet, SmallCapVoice, Wall Street Resources, Planet Penny Stocks, SecretStockPromo, and StockOnion reported earlier on Ecosphere Technologies, Inc. (ESPH), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Ecosphere Technologies, Inc. is a development and Intellectual Property (IP) licensing company. It develops environmental solutions for global water, energy, industrial, and agricultural markets. The Company helps industry increase production, lessen costs, and protect the environment through a portfolio of inventive, patented technologies and exclusive and nonexclusive licensing opportunities across a wide spectrum of industries and applications globally. Ecosphere Technologies is based in Stuart, Florida.

Ecosphere has a wide-ranging portfolio of patented clean technologies. These can be purchased and licensed for use in large-scale and sustainable applications across industries, nations, and ecosystems. The Company’s technologies include the Ecos PowerCube®, the Ecos GrowCube™, and Ozonix®.

The Ecosphere technologies and products are available via many brands and subsidiaries. These include Sea of Green Systems, Ecosphere Development Company, and Fidelity National Environmental Solutions. The Company’s goal is to help clean energy producers’ gain more control over their water resources, quality, and completion costs through providing effective mobile water recycling solutions.

The Ecosphere Ozonix® Technology provides a chemical-free alternative to high-volume water recycling for a varied range of applications. These range from the oil & natural gas industry and mining to agriculture and municipal wastewater treatment. The oil and natural gas industry is successfully using Ecosphere Technologies’ patented Ozonix® technology to treat and recycle the water used in oil and natural gas well drilling and completion programs.

The Ecos PowerCube® is the world’s largest, mobile, solar-powered generator. It runs on high power photovoltaic panels. These panels extend from its container combined with an easy to set up wind turbine. Energy is stored in onboard batteries.

The Ecos GrowCube® is a state-of-the-art, turn-key, fully-automated "greenhouse". It uses hydroponic growing techniques to maximize the amount of crop production possible in a given footprint. The Ecos GrowCube® incorporates Ecosphere’s patented Ozonix® water treatment technology. In addition, Ecosphere has its Ozonix Sentinel. This is the world's first line of water treatment vessels for cleaning up endangered rivers and lakes.

Sea of Green Systems (SOGS), a subsidiary of Ecosphere Technologies, announced in January 2017 the launch of its SOGS-650X, Full Spectrum LED Growing Light. This light was developed to provide growers with an engineered solution to maximize vegetative growth and flower production for the indoor agriculture and legal marijuana industries.

The SOGS-650X can produce greenhouse-like conditions through providing an average 25 DLI (Daily Light Integral) during the Vegetative and Flowering Cycles, with about 450-650 uMols and 700-900 uMols at the plant canopy during their respective growth cycles. Sea of Green Systems (SOGS) sells high-tech growing equipment, lighting solutions, and nutrients to the Precision Agriculture industry.

Recently, Sea of Green Systems announced that its sublicensee in the agricultural industry, Gulf Coast Organics (GCO), signed an agreement with Wedgworth's, Inc., to be the exclusive distributor in Florida for its Amp Agronomy™ plant nutritional line. Wedgworth's is recognized as Florida's largest custom fertilizer dealer since 1932. Wedgworth's provides custom blended agricultural plant nutrient products across Florida to help farms grow and prosper. CAVISONIX®, developed by SOGS and Ecosphere Technologies, utilizes ultrasonic cavitation to treat fertilizers for increased plant availability.

Ecosphere Technologies, Inc. (ESPH), closed Tuesday's trading session at $0.002, up 42.8571%, on 441,900 volume with 13 trades. The average volume for the last 3 months is 160,623 and the stock's 52-week low/high is $0.0005/$0.018899999.

chart

The QualityStocks Company Corner

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings (TSX.V: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, has developed a unique, proprietary nano-emulsification technology that is anticipated to deliver an initial onset of effects within 10 to 15 minutes for cannabis beverages (http://nnw.fm/eT5Y0). To view the full press release, visit: http://nnw.fm/Kv8hO.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Tuesday's trading session at $5.57, up 1.8282%, on 914,374 volume with 3,140 trades. The average volume for the last 3 months is 1,062,282 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF) is exploring and exploiting new opportunities to increase its reach within the cannabis industry. An article discussing the company reads, “Plus Products is continually looking toward new opportunities to expand its consumer base. This attention to rising opportunities is evident in a recent launch of a new product line that provides consumers with microdosing options (http://nnw.fm/2AsOX). To view the full article, visit: http://nnw.fm/DT5j7.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $3.52, up 2.924%, on 28,413 volume with 93 trades. The average volume for the last 3 months is 49,528 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) will report its first quarter fiscal year 2020 financial results before markets open on Tuesday, August 27, 2019. The Company's unaudited condensed interim financial statements and Management's Discussion and Analysis for the three months ended June 30, 2019 will be available on the Company's profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on the Company's website at www.canopyrivers.com/investors/financials-and-public-filings.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Tuesday's trading session at $2.06, up 10.1604%, on 132,132 volume with 314 trades. The average volume for the last 3 months is 107,141 and the stock's 52-week low/high is $1.73950004/$7.30155992.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based technologies and products to the worldwide life sciences and other industries, recently announced its execution of a contract services agreement with a world-renowned, multibillion-dollar biotherapeutics firm. Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk). Also today, the company announced it will host a teleconference to discuss its Second Quarter 2019 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website approximately one day after the teleconference).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.59, up 12.6087%, on 350 volume with 3 trades. The average volume for the last 3 months is 8,857 and the stock's 52-week low/high is $1.51999998/$4.0999999.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) was highlighted today in a publication from Investorideas.com, examining how the cannabis markets continue to grow globally and across the North American markets. In the U.S. with the possible legalization of recreational use on the radar, large marijuana companies are looking at a $22.7 billion national market by 2023.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Tuesday's trading session at $1.5841, up 1.5449%, on 218,423 volume with 386 trades. The average volume for the last 3 months is 421,974 and the stock's 52-week low/high is $1.5151/$5.20499992.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) this morning announced its projected revenue for the fiscal fourth quarter ended June 30, 2019 and provided guidance for fiscal 2020. Per the update, the company anticipates net revenue of about $19 million and positive adjusted EBITDA for the fourth quarter 2019. To view the full press release, visit: http://nnw.fm/6CutW. Also today, the company was pleased to announce the closing of its acquisition of all of the issued and outstanding shares of privately-held Truverra Inc. ("Truverra") (the "Transaction"). The Transaction was completed by way of a three-cornered amalgamation pursuant to which 2708300 Ontario Ltd., a wholly-owned subsidiary of Supreme Cannabis, amalgamated with Truverra to form a newly amalgamated company ("Amalco") which shall operate under the name "Truverra Inc."

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Tuesday's trading session at $1.088, up 14.5263%, on 1,231,582 volume with 999 trades. The average volume for the last 3 months is 324,820 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. To view the full press release, visit: http://nnw.fm/5Mqgb.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $0.9263, up 7.2852%, on 38,607 volume with 144 trades. The average volume for the last 3 months is 39,493 and the stock's 52-week low/high is $0.640999972/$2.98000001.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade Inc. (OTCQB: SGMD), a supplier of hydroponic and cultivation equipment to operators in the booming industrial hemp sector, has commenced hemp cultivation with Hempistry Inc. in Madison County, Kentucky. Sugarmade also announced that it is exercising its investment option in Hempistry as it intensifies its supplier and investor roles in the market (http://nnw.fm/3uPp6). Also today, NetworkNewsWire released a report on the company detailing how SGMD announced that it is now prepared to complete the first closing of its BZRTH, LLC acquisition. As a major supplier to the hydroponic and hemp cultivation sectors, BZRTH produces more than $30 million in annual revenues. In addition, the company is in the process of organizing a special meeting of shareholders to elect new directors, including at least two independent directors with no “material relationship” to the company. To view the full press release, visit: http://nnw.fm/9MlWL.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.0128, up 12.8748%, on 5,363,096 volume with 154 trades. The average volume for the last 3 months is 3,782,400 and the stock's 52-week low/high is $0.00975/$0.197500005.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA) together with joint venture partner Global Hemp Group Inc. (CSE: GHG) ( OTC: GBHPF) (FRANKFURT: GHG) today announced that their joint venture subsidiary, Covered Bridge Acres Ltd. (“CBA”), has started generating revenue through operations at its hemp farm in Scio, Oregon. To view the full press release, visit: http://nnw.fm/j5Jlu.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Tuesday's trading session at $0.0051, up 6.7169%, on 5,479,145 volume with 144 trades. The average volume for the last 3 months is 8,572,239 and the stock's 52-week low/high is $0.004/$0.039299998.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. A recent scientific review conducted by researchers at Amity University in India has concluded that the legal status of marijuana should be reconsidered given that there is a lot of research suggesting that compounds from marijuana can inhibit the growth of tumors and also aid the management of different forms of cancer.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Tuesday's trading session at $0.3425, up 1.1518%, on 523,157 volume with 110 trades. The average volume for the last 3 months is 185,437 and the stock's 52-week low/high is $0.314099997/$1.52999997.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development ("R&D") license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Tuesday's trading session at $0.85, off by 2.6123%, on 95,800 volume with 153 trades. The average volume for the last 3 months is 73,296 and the stock's 52-week low/high is $0.600000023/$2.24.

Recent News

chart

MustGrow Biologics Corp. (CSE: MGRO)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp..

MustGrow Biologics Corp. (CSE: MGRO) is advancing its efforts to be a standard-bearer in the search for natural remedies to prevent pest damage in high value agricultural crops, including tobacco and cannabis, while news about chemical pesticide injuries continues to trouble the larger industry and its ancillary segments.

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented technology that is a natural biopesticide and biofertilizer for use as a fertilizer, nematicide, pesticide and fungicide. MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The company’s technology provides an all-natural, effective, safe and easy-to-use solution for farmers seeking to raise healthy crops without the use of pesticides.

Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients (http://nnw.fm/Qkz21). For the past 50 years, nematodes have been controlled using chemical nematicides, but the Environmental Protection Agency now restricts or bans many of the chemical?formulations.

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://nnw.fm/3HGuT), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

MustGrow’s technology refines mustard seeds to concentrate the plant’s natural organic compounds that form Allyl isothiocyanate (“AITC”), which serves the plant as a natural defense system against pests and diseases. As a result, MustGrow’s novel product offers first-class performance, is 100 percent natural, and its fertilizer product is listed for organic use by the Organic Materials Review Institute (“OMRI”) under specifications set by the USDA’s National Organic Program.

MustGrow’s initial technology was a granular pre-plant soil biofumigant and biofertilizer containing the active ingredient AITC, a proven nematicide, fungicide and fertilizer. The company has completed 110 independent third-party field trials on fruit and vegetable crops. As a biofertilizer, MustGrow’s product is registered with Health Canada and the EPA in all U.S. states as OMRI-certified. It is also registered for use as a biopesticide by the EPA in key fruit and vegetable growing U.S. states (except California) and with Health Canada. MustGrow is finalizing a new liquid delivery platform with increased concentration of the same active ingredient (AITC) that can be applied through drip lines to meet the demands of today’s growers.

Results of tests completed to date show that MustGrow continues to provide innovative solutions with broad based applications within agriculture. Validated field trial results include:

  • 100 percent control of root-knot nematodes in strawberry crops as compared to methyl bromide
  • 55 percent tomato crop yield increase
  • 95 percent control of Pythium root rot in lettuce fields
  • 70 percent reduction in Verticillium root severity in cucumbers
  • Market Opportunity

Market Opportunity??

MustGrow is also testing the potential application of its technology to the cannabis industry, which is projected to grow to nearly $22 billion in the U.S. by 2020. While there are no uniform guidelines for pesticide use in the cannabis industry, state-by-state regulations in the U.S. do exist which has led to instances of pesticide-tainted cannabis showing up in tested products, leading to recalls and threats of lawsuits. Health Canada recently published regulations for mandatory testing for pesticides in cannabis that are now in effect for all growers.?MustGrow’s?potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Cannabis consumers are increasingly demanding organic products free from chemicals and have shown they are willing to pay a premium for high-quality organic cannabis. MustGrow is currently running cannabis soil trials and is seeking Health Canada approval for use of its product on cannabis.?

Global crop protection is a multibillion-dollar market that is expected to surge over the next five years. Sales of nematicides are set to grow by 33 percent to $1.43 billion by 2022, while biopesticides are projected to leap by 94 percent to an estimated?$9.5 billion by 2022. MustGrow is targeting the global nematicide industry with products that include an innovative pre-plant soil treatment. Solutions for the global biopesticide industry include seed treatment technologies, fungicides and nematicides.??

MustGrow’s groundbreaking technologies use novel plant compounds to provide superior crop protection naturally.

Management Team

President and CEO Corey Giasson is an entrepreneur with more than 20 years in the agriculture, potash, oil and gas, mining and real estate industries.? Mr. Giasson co-founded Rallyemont Energy Inc., a heavy oil company that successfully identified 140 million barrels of recoverable heavy oil, that was sold in 2013 to Husky Energy. He holds an MBA and bachelor’s degree in agricultural economics from the University of Saskatchewan.

Chairman Brad Munro has 20-plus years as a vice president/investments, with a national venture capital firm where he sourced, invested and managed the activity of over 30 companies and invested $150 million. He has served as a director of over 20 public companies and a greater number of private enterprises. Munro is currently director of Secure Energy Services.

COO Colin Betsky is the previous vice president/BioAg at Novozymes, where he was responsible for the company’s BioAg business worldwide. He holds a bachelor’s degree in agriculture from the University of Saskatchewan and has more than 20 years of experience in agricultural chemicals and biologics.

Director Tom Flow is the founder and current president of The Flowr Corporation (TSX.V: FLWR) and Licensed Producer of cannabis in Canada. He founded and built MedReleaf, Canada’s most profitable Licensed Producer which was later acquired by Aurora Cannabis?(TSX: ACB) (NYSE: ACB) for $3.2 billion. Flow is widely recognized for his leadership and expertise in building and operating cannabis cultivation facilities.

Director Matt Kowalski has a tremendous amount of experience in the fruit and vegetable and biologics industries. Under his leadership at Natural Industries, a business focused on biological pest control, the company was awarded five EPA registrations: three biofungicides, a bionematicide, and a bioinsecticide. In November 2012, Kowalski led the strategic sale of Natural Industries to Novozymes BioAg. He is the principal owner of Stronghold Keep Inc., an investment corporation.

CFO Todd Lahti has extensive experience evaluating and managing start-up companies in the biotechnology, agricultural and oil and gas sectors, working directly on financing transactions, mergers and acquisitions, corporate strategy, business development, technology transfer and operations set up. He is a Chartered Financial Analyst and a Chartered Professional Accountant.

MustGrow Biologics Corp. (CSE: MGRO), closed Tuesday's trading session at $0.33, off by 2.94%, on 47,560 volume with 5 trades. The average volume for the last 3 months is 75,492 and the stock's 52-week low/high is $0.25/$0.699999988.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint (OTCQB: SING) engages in the acquisition of small to mid-sized firms, with a focus on new technologies. Through its SingleSeed subsidiary, the company provides products and services to the cannabis industry. To view the full article, visit: http://nnw.fm/8EcsE.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.01335, off by 1.1111%, on 2,583,639 volume with 83 trades. The average volume for the last 3 months is 5,783,267 and the stock's 52-week low/high is $0.009999999/$0.041000001.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the second quarter ended June 30, 2019. Alan Collier, Endonovo’s chief executive officer, stated, “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the PEMF assets and technology in December 2017, and I am additionally excited to announce the results we attained throughout the first six months of this year.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Tuesday's trading session at $0.0101, off by 2.8846%, on 4,598,438 volume with 66 trades. The average volume for the last 3 months is 6,492,598 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.